{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:32:27Z","timestamp":1787506347804,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["Clinical Research Professor"],"award-info":[{"award-number":["Clinical Research Professor"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","award":["Career Development Award"],"award-info":[{"award-number":["Career Development Award"]}],"id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA263549"],"award-info":[{"award-number":["K08CA263549"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00520-024-08868-7","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T17:04:40Z","timestamp":1727283880000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Learning about and living with toxicity: a qualitative study of patients receiving immune checkpoint inhibitors for melanoma or lung cancer and their caregivers"],"prefix":"10.1007","volume":"32","author":[{"given":"Ayo S.","family":"Falade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary C.","family":"Boulanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshni","family":"Sarathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riley","family":"Fadden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Traeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Temel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Greer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Petrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"key":"8868_CR1","unstructured":"FDA approves first immunotherapy treatment for lung cancer - NCI [Internet] (2015) Available from: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2015\/fda-opdivo. Accessed 3\u00a0Jan 2023"},{"issue":"5","key":"8868_CR2","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3390\/jcm9051362","volume":"9","author":"K Onoi","year":"2020","unstructured":"Onoi K, Chihara Y, Uchino J, Shimamoto T, Morimoto Y, Iwasaku M et al (2020) Immune checkpoint inhibitors for lung cancer treatment: a review. J Clin Med 9(5):1362","journal-title":"J Clin Med"},{"issue":"8","key":"8868_CR3","doi-asserted-by":"crossref","first-page":"e2225459","DOI":"10.1001\/jamanetworkopen.2022.25459","volume":"5","author":"N Lamba","year":"2022","unstructured":"Lamba N, Ott PA, Iorgulescu JB (2022) Use of first-line immune checkpoint inhibitors and association with overall survival among patients with metastatic melanoma in the anti\u2013PD-1 era. JAMA Netw Open 5(8):e2225459","journal-title":"JAMA Netw Open"},{"issue":"15","key":"8868_CR4","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","volume":"25","author":"DB Doroshow","year":"2019","unstructured":"Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L et al (2019) Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res Off J Am Assoc Cancer Res 25(15):4592\u20134602","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"17","key":"8868_CR5","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1158\/1078-0432.CCR-18-1550","volume":"25","author":"SA Weiss","year":"2019","unstructured":"Weiss SA, Wolchok JD, Sznol M (2019) Immunotherapy of melanoma: facts and hopes. Clin Cancer Res 25(17):5191\u20135201","journal-title":"Clin Cancer Res"},{"key":"8868_CR6","unstructured":"ASCO Daily News [Internet] (2023) Immune-related adverse events: what is their effect on efficacy, patient quality of life, and health care burden? Available from: https:\/\/dailynews.ascopubs.org\/do\/10.1200\/ADN.23.201318\/full. Accessed 3\u00a0Oct 2023"},{"issue":"176","key":"8868_CR7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2022.08.029","volume":"1","author":"TU Schulz","year":"2022","unstructured":"Schulz TU, Zierold S, Sachse MM, Pesch G, Tomsitz D, Schilbach K et al (2022) Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: prevalence and impact on patients\u2019 health-related quality of life. Eur J Cancer 1(176):88\u201399","journal-title":"Eur J Cancer"},{"issue":"5","key":"8868_CR8","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/jgs.15750","volume":"67","author":"E Muchnik","year":"2019","unstructured":"Muchnik E, Loh KP, Strawderman M, Magnuson A, Mohile SG, Estrah V et al (2019) Immune checkpoint inhibitors in real-world treatment of older adults with non\u2013small cell lung cancer. J Am Geriatr Soc 67(5):905\u2013912","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"8868_CR9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s41927-022-00297-5","volume":"6","author":"A Lusa","year":"2022","unstructured":"Lusa A, Alvarez C, Saxena Beem S, Schwartz TA, Ishizawar R (2022) Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy. BMC Rheumatol 6(1):64","journal-title":"BMC Rheumatol"},{"issue":"10","key":"8868_CR10","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/ard-2022-222186","volume":"81","author":"L Pla\u00e7ais","year":"2022","unstructured":"Pla\u00e7ais L, Dalle S, Dereure O, Trabelsi S, Dalac S, Legoupil D et al (2022) Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study. Ann Rheum Dis 81(10):1445\u20131452","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"8868_CR11","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol Off J Am Soc Clin Oncol 36(17):1714\u20131768","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"8868_CR12","doi-asserted-by":"crossref","first-page":"e1190","DOI":"10.1634\/theoncologist.2018-0820","volume":"24","author":"A Wong","year":"2019","unstructured":"Wong A, Billett A, Milne D (2019) Balancing the hype with reality: what do patients with advanced melanoma consider when making the decision to have immunotherapy? Oncologist 24(11):e1190\u2013e1196","journal-title":"Oncologist"},{"key":"8868_CR13","unstructured":"Best practices: education for patients with advanced NSCLC treated with immune checkpoint inhibitors (2023) Available from: https:\/\/www.personalizedmedonc.com\/supplements\/best-practices-education-for-patients-with-advanced-nsclc-treated-with-immune-checkpoint-inhibitors\/232540:best-practices-education-for-patients-with-advanced-nsclc-treated-with-immune-checkpoint-inhibitors. Accessed 4\u00a0Sept 2023"},{"issue":"11","key":"8868_CR14","doi-asserted-by":"crossref","first-page":"e2090","DOI":"10.1002\/onco.13945","volume":"26","author":"LA Petrillo","year":"2021","unstructured":"Petrillo LA, Zhou AZ, Sullivan R, Volandes A, Greer JA, Temel JS et al (2021) Knowledge about risks, benefits, and curative potential of immunotherapy among patients with advanced cancer. Oncologist 26(11):e2090\u2013e2093","journal-title":"Oncologist"},{"issue":"12","key":"8868_CR15","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1007\/s00432-020-03336-1","volume":"146","author":"A Ihrig","year":"2020","unstructured":"Ihrig A, Richter J, Gr\u00fcllich C, Apostolidis L, Horak P, Villalobos M et al (2020) Patient expectations are better for immunotherapy than traditional chemotherapy for cancer. J Cancer Res Clin Oncol 146(12):3189\u20133198","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"8868_CR16","doi-asserted-by":"crossref","first-page":"e1355","DOI":"10.1200\/OP.20.00010","volume":"16","author":"F Riaz","year":"2020","unstructured":"Riaz F, Gan G, Li F, Davidoff AJ, Adelson KB, Presley CJ et al (2020) Adoption of immune checkpoint inhibitors and patterns of care at the end of life. JCO Oncol Pract 16(11):e1355\u2013e1370","journal-title":"JCO Oncol Pract"},{"issue":"16_suppl","key":"8868_CR17","doi-asserted-by":"crossref","first-page":"6566","DOI":"10.1200\/JCO.2023.41.16_suppl.6566","volume":"41","author":"KH Al-Rabi","year":"2023","unstructured":"Al-Rabi KH, Maakoseh M, Jaddoua S, Salah S, Alta\u2019ani O, Yasin A et al (2023) Trends of using immune checkpoint inhibitors near end of life in limited resources setting: experience of single cancer center in the MENA region. J Clin Oncol. 41(16_suppl):6566\u20136566","journal-title":"J Clin Oncol."},{"issue":"6","key":"8868_CR18","doi-asserted-by":"crossref","first-page":"e849","DOI":"10.1200\/OP.21.00689","volume":"18","author":"MD Bloom","year":"2022","unstructured":"Bloom MD, Saker H, Glisch C, Ramnaraign B, George TJ, Markham MJ et al (2022) Administration of immune checkpoint inhibitors near the end of life. JCO Oncol Pract 18(6):e849\u2013e856","journal-title":"JCO Oncol Pract"},{"key":"8868_CR19","first-page":"825859722107839","volume":"7","author":"HM O\u2019Sullivan","year":"2022","unstructured":"O\u2019Sullivan HM, Conroy M, Power DG, Bambury RM, O\u2019Mahony D, Collins DC et al (2022) Immune checkpoint inhibitors and palliative care at the end of life: an Irish multicentre retrospective study. J Palliat Care 7:8258597221078391","journal-title":"J Palliat Care"},{"issue":"10","key":"8868_CR20","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1002\/cncr.32782","volume":"126","author":"LA Petrillo","year":"2020","unstructured":"Petrillo LA, El-Jawahri A, Nipp RD, Lichtenstein MRL, Durbin SM, Reynolds KL et al (2020) Performance status and end-of-life care among adults with non\u2013small cell lung cancer receiving immune checkpoint inhibitors. Cancer 126(10):2288\u20132295","journal-title":"Cancer"},{"issue":"10","key":"8868_CR21","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/oncolo\/oyad219","volume":"28","author":"RN Grad","year":"2023","unstructured":"Grad RN, Jung S, Ye F, Sun L, Johnson DB, Agarwal R (2023) Prognostic risk stratification and end-of-life care outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors. Oncologist 28(10):911\u2013916","journal-title":"Oncologist"},{"issue":"12","key":"8868_CR22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/15265161.2019.1675799","volume":"19","author":"CR Perumalswami","year":"2019","unstructured":"Perumalswami CR, Jagsi R, Goold SD (2019) Predicting a \u201cLazarus Effect\u201d in patients with advanced cancer near the end of life: prognostic uncertainty, oncologists\u2019 emotions, and ethical questions. Am J Bioeth AJOB 19(12):57\u201360","journal-title":"Am J Bioeth AJOB"},{"issue":"1","key":"8868_CR23","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s13046-019-1266-0","volume":"38","author":"S Kruger","year":"2019","unstructured":"Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S et al (2019) Advances in cancer immunotherapy 2019 \u2013 latest trends. J Exp Clin Cancer Res 38(1):268","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"8868_CR24","doi-asserted-by":"crossref","first-page":"575472","DOI":"10.3389\/fonc.2020.575472","volume":"9","author":"R Bai","year":"2020","unstructured":"Bai R, Li L, Chen X, Chen N, Song W, Cui J (2020) Neoadjuvant and adjuvant immunotherapy: opening new horizons for patients with early-stage non-small cell lung cancer. Front Oncol 9(10):575472","journal-title":"Front Oncol"},{"key":"8868_CR25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/EDBK_349411","volume":"42","author":"EA Mittendorf","year":"2022","unstructured":"Mittendorf EA, Burgers F, Haanen J, Cascone T (2022) Neoadjuvant immunotherapy: leveraging the immune system to treat early-stage disease. Am Soc Clin Oncol Educ Book 42:189\u2013203","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"8868_CR26","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/diseases10030060","volume":"10","author":"AK Mishra","year":"2022","unstructured":"Mishra AK, Ali A, Dutta S, Banday S, Malonia SK (2022) Emerging trends in immunotherapy for cancer. Diseases 10(3):60","journal-title":"Diseases"},{"issue":"14","key":"8868_CR27","doi-asserted-by":"crossref","first-page":"11849","DOI":"10.3390\/ijms241411849","volume":"24","author":"E Boydell","year":"2023","unstructured":"Boydell E, Sandoval JL, Michielin O, Obeid M, Addeo A, Friedlaender A (2023) Neoadjuvant immunotherapy: a promising new standard of care. Int J Mol Sci 24(14):11849","journal-title":"Int J Mol Sci"},{"issue":"6","key":"8868_CR28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J (2007) Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 19(6):349\u2013357","journal-title":"Int J Qual Health Care"},{"issue":"3","key":"8868_CR29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11606-010-1552-1","volume":"26","author":"U Sarkar","year":"2011","unstructured":"Sarkar U, Schillinger D, L\u00f3pez A, Sudore R (2011) Validation of self-reported health literacy questions among diverse english and spanish-speaking populations. J Gen Intern Med 26(3):265\u2013271","journal-title":"J Gen Intern Med"},{"issue":"8","key":"8868_CR30","first-page":"588","volume":"36","author":"LD Chew","year":"2004","unstructured":"Chew LD, Bradley KA, Boyko EJ (2004) Brief questions to identify patients with inadequate health literacy. Fam Med 36(8):588\u2013594","journal-title":"Fam Med"},{"issue":"2","key":"8868_CR31","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377\u2013381","journal-title":"J Biomed Inform"},{"issue":"1","key":"8868_CR32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1471-2288-13-117","volume":"13","author":"NK Gale","year":"2013","unstructured":"Gale NK, Heath G, Cameron E, Rashid S, Redwood S (2013) Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol 13(1):117","journal-title":"BMC Med Res Methodol"},{"key":"8868_CR33","unstructured":"What is inductive coding in qualitative research? [Internet] (2023) Available from: https:\/\/dovetail.com\/research\/inductive-coding\/. Accessed 16\u00a0Jan 2024"},{"key":"8868_CR34","unstructured":"Flick U, Kardoff E von, Steinke I (2004) A companion to qualitative research.\u00a0SAGE, London, p 447"},{"issue":"33","key":"8868_CR35","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1200\/JCO.2007.15.2322","volume":"26","author":"J Jansen","year":"2008","unstructured":"Jansen J, Butow PN, van Weert JCM, van Dulmen S, Devine RJ, Heeren TJ et al (2008) Does age really matter? Recall of information presented to newly referred patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol 26(33):5450\u20135457","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"8868_CR36","doi-asserted-by":"crossref","first-page":"151445","DOI":"10.1016\/j.soncn.2023.151445","volume":"39","author":"SM Teixeira-Poit","year":"2023","unstructured":"Teixeira-Poit SM, Sawicki K, O\u2019Kelley W, Hardin M, Jenkins M, Gudena V (2023) Efficacy of a patient education session for cancer patients receiving immunotherapy. Semin Oncol Nurs 39(4):151445","journal-title":"Semin Oncol Nurs"},{"issue":"5","key":"8868_CR37","doi-asserted-by":"crossref","first-page":"150933","DOI":"10.1016\/j.soncn.2019.08.012","volume":"35","author":"M Lasa-Blandon","year":"2019","unstructured":"Lasa-Blandon M, Stasi K, Hehir A, Fischer-Cartlidge E (2019) Patient education issues and strategies associated with immunotherapy. Semin Oncol Nurs 35(5):150933","journal-title":"Semin Oncol Nurs"},{"issue":"16_suppl","key":"8868_CR38","doi-asserted-by":"crossref","first-page":"e24046","DOI":"10.1200\/JCO.2023.41.16_suppl.e24046","volume":"41","author":"M Canning","year":"2023","unstructured":"Canning M, Liu Y, Aldrich J, Switchenko JM, Bhave MA (2023) Patient understanding of immunotherapy and its side effects for women with triple negative breast cancer. J Clin Oncol 41(16_suppl):e24046\u2013e24046","journal-title":"J Clin Oncol"},{"issue":"110","key":"8868_CR39","doi-asserted-by":"crossref","first-page":"107640","DOI":"10.1016\/j.pec.2023.107640","volume":"1","author":"M Nicolas-Joseph","year":"2023","unstructured":"Nicolas-Joseph M, Ould Brahim L, Boureanu MI, Frati FYE, Bourdache LR, Belzile E et al (2023) An evaluation of the suitability, readability, quality, and usefulness of online resources for patients with cancer receiving immunotherapy. Patient Educ Couns 1(110):107640","journal-title":"Patient Educ Couns"},{"issue":"4","key":"8868_CR40","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/cer-2016-0077","volume":"6","author":"C Stepanczuk","year":"2017","unstructured":"Stepanczuk C, Williams N, Morrison K, Kemmerer C (2017) Factors influencing patients\u2019 receptiveness to evidence-based recommendations during the clinical encounter. J Comp Eff Res 6(4):347\u2013361","journal-title":"J Comp Eff Res"},{"issue":"2","key":"8868_CR41","first-page":"145","volume":"2","author":"M Glajchen","year":"2004","unstructured":"Glajchen M (2004) The emerging role and needs of family caregivers in cancer care. J Support Oncol 2(2):145\u2013155","journal-title":"J Support Oncol"},{"key":"8868_CR42","doi-asserted-by":"crossref","first-page":"102134","DOI":"10.1016\/j.ctrv.2020.102134","volume":"92","author":"S Hussaini","year":"2021","unstructured":"Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S et al (2021) Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis. Cancer Treat Rev 92:102134","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"8868_CR43","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.21037\/jtd.2020.04.30","volume":"12","author":"M Sung","year":"2020","unstructured":"Sung M, Zer A, Walia P, Khoja L, Maganti M, Labbe C et al (2020) Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. J Thorac Dis 12(5):2706\u20132712","journal-title":"J Thorac Dis"},{"issue":"9","key":"8868_CR44","doi-asserted-by":"crossref","first-page":"e787","DOI":"10.1200\/JOP.18.00787","volume":"15","author":"DL Hall","year":"2019","unstructured":"Hall DL, Jimenez RB, Perez GK, Rabin J, Quain K, Yeh GY et al (2019) Fear of cancer recurrence: a model examination of physical symptoms, emotional distress, and health behavior change. J Oncol Pract 15(9):e787\u2013e797","journal-title":"J Oncol Pract"},{"issue":"1","key":"8868_CR45","doi-asserted-by":"crossref","first-page":"e000112","DOI":"10.1136\/jitc-2019-000112","volume":"8","author":"S Pai","year":"2020","unstructured":"Pai S, Blaisdell D, Brodie R, Carlson R, Finnes H, Galioto M et al (2020) Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit. J Immunother Cancer 8(1):e000112","journal-title":"J Immunother Cancer"},{"issue":"1","key":"8868_CR46","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1186\/s12885-020-07215-3","volume":"20","author":"L Jamieson","year":"2020","unstructured":"Jamieson L, Forster MD, Zaki K, Mithra S, Alli H, O\u2019Connor A et al (2020) Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study. BMC Cancer 20(1):743","journal-title":"BMC Cancer"},{"issue":"1","key":"8868_CR47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41687-024-00700-4","volume":"8","author":"NR Dickson","year":"2024","unstructured":"Dickson NR, Beauchamp KD, Perry TS, Roush A, Goldschmidt D, Edwards ML et al (2024) Real-world use and clinical impact of an electronic patient-reported outcome tool in patients with solid tumors treated with immuno-oncology therapy. J Patient-Rep Outcomes 8(1):23","journal-title":"J Patient-Rep Outcomes"},{"issue":"24","key":"8868_CR48","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/jama.2022.9265","volume":"327","author":"E Basch","year":"2022","unstructured":"Basch E, Schrag D, Henson S, Jansen J, Ginos B, Stover AM et al (2022) Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial. JAMA 327(24):2413\u20132422","journal-title":"JAMA"},{"key":"8868_CR49","doi-asserted-by":"crossref","first-page":"e2200185","DOI":"10.1200\/CCI.22.00185","volume":"7","author":"J Lai-Kwon","year":"2023","unstructured":"Lai-Kwon J, Cohen JE, Lisy K, Rutherford C, Girgis A, Basch E et al (2023) The feasibility, acceptability, and effectiveness of electronic patient-reported outcome symptom monitoring for immune checkpoint inhibitor toxicities: a systematic review. JCO Clin Cancer Inform 7:e2200185","journal-title":"JCO Clin Cancer Inform"},{"issue":"8","key":"8868_CR50","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s00520-023-07934-w","volume":"31","author":"AM da Silva Lopes","year":"2023","unstructured":"da Silva Lopes AM, Colomer-Lahiguera S, Darnac C, Giacomini S, Bugeia S, Gutknecht G et al (2023) Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors. Support Care Cancer 31(8):484","journal-title":"Support Care Cancer"},{"key":"8868_CR51","doi-asserted-by":"crossref","unstructured":"Lopes AM da S, Colomer-Lahiguera S, Darnac C, Giacomini S, Bugeia S, Gutknecht G et al (2023) Testing a model of care for patients on immune checkpoint inhibitors based on electronic patient-reported outcomes: protocol for a randomized phase ii controlled trial. Jmir Res Protoc 12(1):e4838","DOI":"10.2196\/48386"},{"key":"8868_CR52","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/978-1-4419-1428-6_530","volume-title":"Encyclopedia of the sciences of learning [Internet]","author":"A Sharp","year":"2012","unstructured":"Sharp A (2012) Humanistic Approaches to Learning. In: Seel NM (ed) Encyclopedia of the sciences of learning [Internet]. Springer, US, Boston, MA, pp 1469\u201371. https:\/\/doi.org\/10.1007\/978-1-4419-1428-6_530 [cited 2023 Oct 30]"},{"key":"8868_CR53","unstructured":"Lippitt GL, Knowles MS, Knowles MS (1984) Andragogy in action: applying modern principles of adult learning.\u00a0Jossey Bass, San Francisco"},{"issue":"6","key":"8868_CR54","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1200\/JCO.2006.06.7827","volume":"25","author":"JM Clayton","year":"2007","unstructured":"Clayton JM, Butow PN, Tattersall MHN, Devine RJ, Simpson JM, Aggarwal G et al (2007) Randomized controlled trial of a prompt list to help advanced cancer patients and their caregivers to ask questions about prognosis and end-of-life care. J Clin Oncol Off J Am Soc Clin Oncol 25(6):715\u2013723","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"8868_CR55","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/j.1525-1497.2006.00544.x","volume":"21","author":"MK Paasche-Orlow","year":"2006","unstructured":"Paasche-Orlow MK, Schillinger D, Greene SM, Wagner EH (2006) How health care systems can begin to address the challenge of limited literacy. J Gen Intern Med 21(8):884\u2013887","journal-title":"J Gen Intern Med"},{"key":"8868_CR56","doi-asserted-by":"crossref","first-page":"205520762211290","DOI":"10.1177\/20552076221129079","volume":"8","author":"A de Wit","year":"2022","unstructured":"de Wit A, de Heide J, Cummins P, van Bruchem-van de Scheur A, Bhagwandien R, Lenzen M (2022) A quality improvement initiative for patient knowledge comprehension during the discharge procedure using a novel computer-generated patient-tailored discharge document in cardiology. Digit Health. 8:20552076221129080","journal-title":"Digit Health."},{"issue":"1","key":"8868_CR57","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s40425-019-0782-y","volume":"7","author":"MJ Krimphove","year":"2019","unstructured":"Krimphove MJ, Tully KH, Friedlander DF, Marchese M, Ravi P, Lipsitz SR et al (2019) Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. J Immunother Cancer 7(1):289","journal-title":"J Immunother Cancer"},{"issue":"2","key":"8868_CR58","doi-asserted-by":"crossref","first-page":"e001754","DOI":"10.1136\/jitc-2020-001754","volume":"8","author":"A Naing","year":"2020","unstructured":"Naing A, Hajjar J, Gulley JL, Atkins MB, Ciliberto G, Meric-Bernstam F et al (2020) Strategies for improving the management of immune-related adverse events. J Immunother Cancer 8(2):e001754","journal-title":"J Immunother Cancer"},{"issue":"31","key":"8868_CR59","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2017.75.2311","volume":"35","author":"T Gilligan","year":"2017","unstructured":"Gilligan T, Coyle N, Frankel RM, Berry DL, Bohlke K, Epstein RM et al (2017) Patient-clinician communication: American Society of Clinical Oncology Consensus Guideline. J Clin Oncol 35(31):3618\u20133632","journal-title":"J Clin Oncol"},{"key":"8868_CR60","doi-asserted-by":"crossref","unstructured":"Cappella JN, Street RL Jr. Delivering Effective Messages in the Patient-Clinician Encounter.\u00a0 JAMA. 2024 Mar 5;331(9):792\u20133","DOI":"10.1001\/jama.2024.0371"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08868-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08868-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08868-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:24:40Z","timestamp":1729297480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08868-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["8868"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08868-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,24]]},"assertion":[{"value":"13 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"684"}}